230 related articles for article (PubMed ID: 25440089)
1. E2F4 regulatory program predicts patient survival prognosis in breast cancer.
Khaleel SS; Andrews EH; Ung M; DiRenzo J; Cheng C
Breast Cancer Res; 2014 Dec; 16(6):486. PubMed ID: 25440089
[TBL] [Abstract][Full Text] [Related]
2. The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.
Mark KMK; Varn FS; Ung MH; Qian F; Cheng C
BMC Cancer; 2017 May; 17(1):306. PubMed ID: 28464832
[TBL] [Abstract][Full Text] [Related]
3. ER
Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
[No Abstract] [Full Text] [Related]
4. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
5. A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction.
Yao K; Tong CY; Cheng C
Sci Rep; 2022 Feb; 12(1):2211. PubMed ID: 35140308
[TBL] [Abstract][Full Text] [Related]
6. The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy.
Bertucci F; Finetti P; Birnbaum D
Breast Cancer Res; 2015 Apr; 17(1):54. PubMed ID: 25887620
[No Abstract] [Full Text] [Related]
7. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
8. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
[TBL] [Abstract][Full Text] [Related]
9. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
10. Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.
Vallon-Christersson J; Häkkinen J; Hegardt C; Saal LH; Larsson C; Ehinger A; Lindman H; Olofsson H; Sjöblom T; Wärnberg F; Ryden L; Loman N; Malmberg M; Borg Å; Staaf J
Sci Rep; 2019 Aug; 9(1):12184. PubMed ID: 31434940
[TBL] [Abstract][Full Text] [Related]
11. Copy number profiling of Oncotype DX genes reveals association with survival of breast cancer patients.
Ahmed W; Malik MFA; Saeed M; Haq F
Mol Biol Rep; 2018 Dec; 45(6):2185-2192. PubMed ID: 30225582
[TBL] [Abstract][Full Text] [Related]
12. Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions.
Chen L; Chen DT; Kurtyka C; Rawal B; Fulp WJ; Haura EB; Cress WD
J Biol Chem; 2012 Nov; 287(48):40106-18. PubMed ID: 23060449
[TBL] [Abstract][Full Text] [Related]
13. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
Liu D
Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
[TBL] [Abstract][Full Text] [Related]
14. Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression.
Bhawe K; Roy D
Cell Oncol (Dordr); 2018 Oct; 41(5):465-484. PubMed ID: 30047092
[TBL] [Abstract][Full Text] [Related]
15. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
Kuo WH; Chang YY; Lai LC; Tsai MH; Hsiao CK; Chang KJ; Chuang EY
PLoS One; 2012; 7(9):e45831. PubMed ID: 23049873
[TBL] [Abstract][Full Text] [Related]
16. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
[TBL] [Abstract][Full Text] [Related]
19. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
20. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.
Martin KJ; Patrick DR; Bissell MJ; Fournier MV
PLoS One; 2008 Aug; 3(8):e2994. PubMed ID: 18714348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]